Checkpoint inhibitors

Pembrolizumab, nivolumab, ipilimumab, and relatlimab (in a fixed-dose formulation with nivolumab) are checkpoint inhibitors approved by the FDA. Each has demonstrated the ability to impact OS against different comparators in unresectable or advanced disease. Multiple phase III trials are in progress to determine the optimal sequencing of immunotherapies, immunotherapy with targeted therapy, and whether combinations of immunotherapies or immunotherapy plus targeted therapy are superior for increasing OS.